Treatment with methotrexate for 1 year has been shown to delay the development of undifferentiated arthritis into rheumatoid arthritis (RA), particularly in anti-citrullinated protein antibody (ACPA)-positive patients. However, long-term results of the PROMPT study now show that this very early introduction of methotrexate does not improve long-term clinical and radiological outcomes. Progression to classifiable RA, achievement of drug-free remission and radiological progression was similar among patients in the methotrexate (n = 55) and placebo (n = 55) groups at 5 years.
ORIGINAL RESEARCH PAPER
van Aken, J. et al. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202967
Rights and permissions
About this article
Cite this article
5-year outcomes of early intervention for 'probable RA'. Nat Rev Rheumatol 9, 134 (2013). https://doi.org/10.1038/nrrheum.2013.13
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2013.13